Register now
Register to receive full, unrestricted access to our resources, regular updates and partnership opportunities
This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
This episode focuses on collaborative working projects (CWPs) in MS, exploring how partnership approaches can address specific challenges within this therapy area and improve patient care.
Hosted by John Bingham from The Clarion Portfolio, this session brings together expert insights from Jeremy Dixon, Value & Access Marketing Director, and Helen Fotheringham, Solution & Service Design Lead, at Novartis UK. It also features contributions from Judith Wilton, Nurse Consultant in MS at Frimley Health NHS Foundation Trust, shared via pre-recorded clips, highlighting a service redesign project. Together, they offer practical learnings and real-world experience of implementing a CWP within an MS pathway.
The discussion highlights the opportunities CWPs present in transforming services, the considerations involved in delivering successful projects, and the impact of effective collaboration between industry and the NHS.
Explore how this collaboration translated real-world impact within an NHS setting, improving care delivery and supporting more efficient services.
This episode is part of our series exploring the impact of collaborative working in the UK. Discover the other episodes in the series below and hear more about these innovative partnerships in action.
Discover how partnership-led change between the pharmaceutical industry and the NHS is shaping the future of healthcare.
UK | September 2026 | FA-11644717 Fictional patient and healthcare professional images.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.